These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1000139)

  • 1. Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity.
    Van Praag HM; Korf J; Dols LC
    Br J Psychiatry; 1976 Dec; 129():547-55. PubMed ID: 1000139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding other antipsychotics to clozapine.
    Cooke C; de Leon J
    J Clin Psychiatry; 1999 Oct; 60(10):710. PubMed ID: 10549694
    [No Abstract]   [Full Text] [Related]  

  • 3. Clozapine: guidelines for clinical management.
    Lieberman JA; Kane JM; Johns CA
    J Clin Psychiatry; 1989 Sep; 50(9):329-38. PubMed ID: 2670914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years.
    Juul Povlsen U; Noring U; Fog R; Gerlach J
    Acta Psychiatr Scand; 1985 Feb; 71(2):176-85. PubMed ID: 3883696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone.
    Hendouei N; Farnia S; Mohseni F; Salehi A; Bagheri M; Shadfar F; Barzegar F; Hoseini SD; Charati JY; Shaki F
    Biomed Pharmacother; 2018 Jul; 103():965-972. PubMed ID: 29710513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine and schizophrenia. A reappraisal in the light of clinical studies with clozapine.
    Nair NP; Zicherman V; Schwartz G
    Can Psychiatr Assoc J; 1977 Oct; 22(6):285-93. PubMed ID: 21741
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis.
    Small JG; Milstein V; Marhenke JD; Hall DD; Kellams JJ
    J Clin Psychiatry; 1987 Jul; 48(7):263-7. PubMed ID: 2885310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do central antiadrenergic actions contribute to the atypical properties of clozapine?
    Baldessarini RJ; Huston-Lyons D; Campbell A; Marsh E; Cohen BM
    Br J Psychiatry Suppl; 1992 May; (17):12-6. PubMed ID: 1418884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of dopamine metabolism for clinical effects and side effects of neuroleptics.
    Van Praag HM; Korf J
    Am J Psychiatry; 1976 Oct; 133(10):1171-7. PubMed ID: 970488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of clozapine on the mental and somatic state of patients].
    Nurowska K; Paluba M; Welbel
    Psychiatr Pol; 1975; 9(4):423-9. PubMed ID: 1161940
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of clozapine on human serum prolactin levels.
    Meltzer HY; Goode DJ; Schyve PM; Young M; Fang VS
    Am J Psychiatry; 1979 Dec; 136(12):1550-5. PubMed ID: 507205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical research into psychosis.
    van Praag HM; Korf J
    Acta Psychiatr Scand; 1975 May; 51(4):268-84. PubMed ID: 238363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clozapine and the dopamine hypothesis of schizophrenia, a critical appraisal.
    Bürki HR; Eichenberger E; Sayers AC; White TG
    Pharmakopsychiatr Neuropsychopharmakol; 1975 May; 8(3):115-21. PubMed ID: 1241920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clozapine and resistant schizophrenia].
    Pere JJ; Chaumet-Riffaud D
    Encephale; 1990; 16(2):143-5. PubMed ID: 1972053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clozapine: benefits and risks.
    Green AI; Salzman C
    Hosp Community Psychiatry; 1990 Apr; 41(4):379-80. PubMed ID: 2158938
    [No Abstract]   [Full Text] [Related]  

  • 16. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses.
    Gaertner I; Altendorf K; Batra A; Gaertner HJ
    J Clin Psychopharmacol; 2001 Apr; 21(2):215-22. PubMed ID: 11270919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroleptic malignant syndrome during perphenazine treatment.
    Nielsen D; Aunsholt NA; Andersen PT
    Pharmacol Toxicol; 1987 Mar; 60(3):221-2. PubMed ID: 3588517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EEG profile and behavioral changes after a single dose of clozapine in normals and schizophrenics.
    Roubicek J; Major I
    Biol Psychiatry; 1977 Oct; 12(5):613-33. PubMed ID: 338039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and behavioural properties of clozapine.
    Coward DM; Imperato A; Urwyler S; White TG
    Psychopharmacology (Berl); 1989; 99 Suppl():S6-12. PubMed ID: 2573106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of clozapine response in schizophrenia.
    Pickar D; Owen RR; Litman RE; Hsiao JK; Su TP
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():129-32. PubMed ID: 7525541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.